Cemiplimab Plus Gemcitabine
Phase 2Recruiting 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreatic Ductal Adenocarcinoma (mPDAC)
Conditions
Pancreatic Ductal Adenocarcinoma (mPDAC)
Trial Timeline
Jan 1, 2026 → Dec 1, 2029
NCT ID
NCT06790602About Cemiplimab Plus Gemcitabine
Cemiplimab Plus Gemcitabine is a phase 2 stage product being developed by Regeneron Pharmaceuticals for Pancreatic Ductal Adenocarcinoma (mPDAC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06790602. Target conditions include Pancreatic Ductal Adenocarcinoma (mPDAC).
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06790602 | Phase 2 | Recruiting |
Competing Products
20 competing products in Pancreatic Ductal Adenocarcinoma (mPDAC)